Health Care

What Analyst Recommends about: Juno Therapeutics, Inc. (NASDAQ:JUNO)

0 11

Juno Therapeutics, Inc. (NASDAQ:JUNO) closed its last session at $28.47 with the change of +0.18%. The market capitalization of the company is $2.90B with an average Volume of 2.19 million shares. The stock currently has its 52-Week High range of $57.82 and 52-week low range of $22.37. The Price to Book (P/B) ratio stands at 2.50. The stock traded total quantity of 1.29 million shares.

Currently Juno Therapeutics, Inc. (JUNO) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “7″ Analysts”. “1” rated “Sell” for the company. “4” said the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $43.77 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $61.00 however minimum price target advised by analysts is $23.00. The Median price target for the stock is measured at $45.00.

Presently, Analysts decided consensus EPS estimate of $-0.64 for present quarter and one month ago projected EPS estimate was at $-0.64. If we take a look at back 3 month ago, consensus EPS estimate was $-0.51.

A current consensus EPS estimate for next quarter is at $-0.67 and 3 month ago EPS forecast was $-0.54. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.67.

For current fiscal year, most recent EPS estimate is set at $-2.68 based on Analyst consensus and three month ago consensus EPS opinions was at $-2.24. During period one month ago, consensus EPS forecast was decided at $-2.66.

A current consensus EPS projection for next fiscal year is observed at $-2.84 and one month ago consensus EPS forecast was at $-2.82. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-2.51 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 7 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 4 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 8 said a “Buy Rating” and 1 announced “Overweight Rating”. 2 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.